Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OH2 intratumoral injection plus investigator-chosen chemotherapy in advanced biliary tract cancer
CTR20232165Phase 2Terminated
- Sponsor
- Wuhan Binhui Biopharmaceutical Co., Ltd.
- Start
- Jul 2023
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Vaccines & Immunotherapeutics, Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of OH2 in biliary cancer, gallbladder cancer, intrahepatic cholangiocarcinoma (ICC), extrahepatic cholangiocarcinoma (eCCA), Ampullary cancer (AC), sponsored by Wuhan Binhui Biopharmaceutical Co., Ltd.. Started Jul 2023; status: terminated.
02
Drugs
OH2
03
Conditions
biliary cancergallbladder cancerintrahepatic cholangiocarcinoma (ICC)extrahepatic cholangiocarcinoma (eCCA)Ampullary cancer (AC)
Beyond the preview
Go deeper on CTR20232165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232165.